Andy Chen
Stock Analyst at Wolfe Research
(3.43)
# 880
Out of 5,182 analysts
42
Total ratings
50%
Success rate
23.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $12 → $24 | $17.36 | +38.25% | 4 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $40.86 | +115.37% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $84.34 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $24.50 | +104.08% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $85.40 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $438.71 | +24.91% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $746.75 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $13.13 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $40.41 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $318.85 | - | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $73.15 | -33.01% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $23.23 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $57.68 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $37.23 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $53.31 | -62.48% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $21.46 | -11.46% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $95.93 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $31.06 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $546.89 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.84 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $74.79 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $49.51 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $28.33 | -39.99% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $162.43 | -74.14% | 1 | Feb 15, 2024 |
MoonLake Immunotherapeutics
Mar 23, 2026
Upgrades: Outperform
Price Target: $12 → $24
Current: $17.36
Upside: +38.25%
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $40.86
Upside: +115.37%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $84.34
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $24.50
Upside: +104.08%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $85.40
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $438.71
Upside: +24.91%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $746.75
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.13
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $40.41
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $318.85
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $73.15
Upside: -33.01%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $23.23
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $57.68
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $37.23
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $53.31
Upside: -62.48%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $21.46
Upside: -11.46%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $95.93
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $31.06
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $546.89
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $18.84
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $74.79
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $49.51
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $28.33
Upside: -39.99%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $162.43
Upside: -74.14%